| Description: |
(Rac)-Benpyrine, a racemate of Benpyrine, is a potent and orally active TNF-α inhibitor. (Rac)-Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research[1]. |
| Target: |
TNF-α |
| In Vivo: |
(Rac)-Benpyrine (Compound 001; 25-50 mg/kg; oral gavage; daily; for 3 weeks; Kunming mice) treatment obviously reduces the inflammatory cytokines IFN-γ, IL-1β and IL-6 in the blood serum, and the anti-inflammatory factor IL-10 is obviously increased, the foot swelling degree of the arthritis part is also obviously slowed down, and the weight index increase caused by the arthritis also has no obvious reduction[1]. Animal Model: Kunming mice (7-8 weeks) treated with bovine type II collagen and a CFA complete adjuvant[1] Dosage: 25 mg/kg, 50 mg/kg Administration: Oral gavage; daily; for 3 weeks Result: The inflammatory cytokines IFN-γ, IL-1β and IL-6 in the blood serum were obviously reduced, and the anti-inflammatory factor IL-10 was obviously increased. |
| In Vitro: |
(Rac)-Benpyrine (Compound 001; 5-10 μM; 24 hours) treatment inhibits the expression level of TNF-α downstream pathway protein NF-κB in the nucleus in RAW264.7 macrophages[1]. |
| References: |
[1]. Hua Li, et al. Compound with TNF- α inhibitory activity and application. CN111320630A. |
